3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Frailty
12
Neoplasms
11
Ovarian Neoplasms
5
Lymphoma
5
Lung Neoplasms
4
Breast Neoplasms
4
Prostatic Neoplasms
3
Multiple Myeloma
3
Carcinoma, Non-Small-Cell Lung
3
Lymphoma, Large B-Cell, Diffuse
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Treatment Adherence and Compliance
1
Stomach Neoplasms
1
Solid Neoplasm
1
Sarcopenia
1
Sarcoma
1
Recurrence
1
Prostate Cancer Cured
1
Postoperative Complications
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Interventions
Cyclophosphamide
77
Dexamethasone
74
Melphalan
65
Lenalidomide
50
Bortezomib
50
Peripheral Blood Stem Cell Transplantation
49
fludarabine phosphate
47
Busulfan
46
Filgrastim
39
Tacrolimus
37
Antilymphocyte Serum
33
Radiotherapy
30
Mycophenolic Acid
30
Thalidomide
28
fludarabine
24
Methotrexate
22
Whole-Body Irradiation
21
Cyclosporine
21
Calcium Dobesilate
21
Granulocyte Colony-Stimulating Factor
18
Methylprednisolone
17
Etoposide
17
Cord Blood Stem Cell Transplantation
14
daratumumab
11
Prednisone
11
Carmustine
11
sargramostim
10
Stem Cell Transplantation
10
Sirolimus
10
Rituximab
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms, Plasma Cell
×
Geriatric Assessment
×
Clear all
NCT05101759
2024-09-25
LYMPHOLD
University Hospital, Toulouse
Phase NA
Completed
100 enrolled